49. Systemic lupus erythematosus Clinical trials / Disease details

Clinical trials : 946 / Drugs : 722 - (DrugBank : 186) / Drug target genes : 117 - Drug target pathways : 199

38 trials found

diseases per page:

Showing 1 to 10 of 38 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCT2071210076	01/11/2021	15/10/2021	A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy a ...	The purpose of this study is evaluating the efficacy and safety of SC antifrolumab in adult patients ...	Systemic Lupus Erythematosus	Approximately 360 patients are planned to be randomly assigned in a 1:1 ratio (180 patients per treat ...	Hibi Kazushige	NULL	Recruiting	>= 18age old	<= 70age old	Both	36	Phase 3	United States;Argentina;Bulgaria;Chile;Colombia;Hungary;Mexico;Peru;Poland;Russia;Ukraine;United Kin ...
2	NCT04931563 (ClinicalTrials.gov)	September 13, 2021	29/4/2021	Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)	A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy ...	Active Systemic Lupus Erythematosus	Biological: Anifrolumab;Drug: placebo	AstraZeneca	NULL	Recruiting	18 Years	70 Years	All	328	Phase 3	China;Hong Kong;Korea, Republic of;Philippines;Taiwan;Thailand
3	EUCTR2020-004529-22-BG (EUCTR)	10/09/2021	23/07/2021	Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy a ...	Moderate-to-severe Systemic Lupus Erythematosus (SLE) MedDRA version: 21.1;Level: PT;Classification ...	Product Name: Anifrolumab Product Code: MEDI-546 INN or Proposed INN: ANIFROLUMAB Other descriptive nam ...	AstraZeneca	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	360	Phase 3	United States;Spain;Ukraine;Chile;Russian Federation;Colombia;United Kingdom;Hungary;Mexico;Argentin ...
4	EUCTR2020-004529-22-HU (EUCTR)	24/08/2021	18/06/2021	Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy a ...	Moderate-to-severe Systemic Lupus Erythematosus (SLE) MedDRA version: 21.1;Level: PT;Classification ...	Product Name: Anifrolumab Product Code: MEDI-546 INN or Proposed INN: ANIFROLUMAB Other descriptive nam ...	AstraZeneca	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	360	Phase 3	United States;Spain;Ukraine;Chile;Russian Federation;Colombia;United Kingdom;Hungary;Mexico;Japan;Ge ...
5	NCT05001698 (ClinicalTrials.gov)	July 27, 2021	30/6/2021	Anifrolumab PK Study for Systemic Lupus Erythematosus (SLE)	A Phase I, Open-label, Single-Arm, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and ...	Systemic Lupus Erythematosus	Biological: Anifrolumab	AstraZeneca	NULL	Active, not recruiting	18 Years	60 Years	All	15	Phase 1	China
6	NCT04750057 (ClinicalTrials.gov)	July 1, 2021	9/2/2021	Anifrolumab Early Access Program	An Early Access Program for AnifrolumabTreatment in Adult Patients With Active Systemic Lupus Erythe ...	Systemic Lupus Erythematosus	Drug: Anifrolumab	AstraZeneca	Clinigen, Inc.	No longer available	18 Years	N/A	All			NULL
7	NCT04877691 (ClinicalTrials.gov)	June 8, 2021	4/5/2021	Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus	A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy a ...	Systemic Lupus Erythematosus	Drug: Medi-546;Drug: Placebo	AstraZeneca	Iqvia Pty Ltd	Recruiting	18 Years	70 Years	All	360	Phase 3	United States;Argentina;Bulgaria;Chile;Colombia;Germany;Hungary;Japan;Mexico;Peru;Poland;Russian Fed ...
8	NCT04726553 (ClinicalTrials.gov)	January 20, 2021	22/1/2021	Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE	Nature of AnifrolumabImpact on Vaccine-Emergent Immunity in Patients With Moderately to Severely Act ...	Systemic Lupus Erythematosus (SLE)	Drug: Anifrolumab;Drug: Standard of Care	Oklahoma Medical Research Foundation	NYU Langone Health;Yale University;Piedmont Heart Institute, Inc., Atlanta, GA;Columbia University	Recruiting	18 Years	70 Years	All	20	Early Phase 1	United States
9	EUCTR2016-000625-39-BG (EUCTR)	17/05/2017	08/03/2017	A study to characterize the safety and tolerability of Anifrolumabin adult patients with Systemic Lu ...	A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise ...	Systemic Lupus Erythematosus MedDRA version: 20.0;Level: PT;Classification code 10042945;Term: Syste ...	Product Name: Anifrolumab Product Code: MEDI-546 INN or Proposed INN: Anifrolumab	AstraZeneca AB	NULL	Not Recruiting			Female: yes Male: yes	575	Phase 3	United States;Taiwan;Spain;Ukraine;Israel;Chile;Russian Federation;Colombia;Italy;France;Australia;P ...
10	JPRN-JapicCTI-173544	26/4/2017	23/03/2017	TULIP SLE LTE	A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise ...	Active Systemic Lupus Erythematosus	Intervention name : Anifrolumab INN of the intervention : anifrolumab Dosage And administration of the ...	AstraZeneca	NULL	complete	18		BOTH	50	Phase 3	Japan, Asia except Japan, North America, South America, Europe, Oceania

First Previous1 2 3 4Next Last